SARS-CoV-2 vaccine testing and trials in the pediatric population

Early on in the SARS-CoV-2 pandemic, the majority of infected children were either asymptomatic or had mild COVID-19 disease, prompting many to demand a higher acceptable risk threshold for pediatric vaccines. More recently, as children begin to make up a larger proportion of the infected population and following evidence of the mental and physical toll exacted by the pandemic on children, a pediatric vaccine is now more pressing. But challenges to widespread vaccine uptake remain. In this episode meet Dr. Chulie Ulloa from the University of California Irvine about a recent commentary she wrote with fellow pediatric providers, physician scientists and advocates for children about these challenges and how they might be overcome.